Literature DB >> 32388604

Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis.

Li-Li Tang1, Wen-Zhe Feng2, Jia-Jun Cheng1, Yan-Ni Gong1.   

Abstract

BACKGROUND: Ulcerative colitis (UC) is a chronic, recurrent and destructive disease of the gastrointestinal tract. Faecal microbiota transplantation (FMT) is a therapeutic measure in which faecal microbiota from healthy people is transplanted into patients. AIM: To systematically evaluate the safety and effectiveness of treating UC with different modes of FMT.
METHODS: Seven databases were searched by two independent researchers and studies related to randomized controlled trials were included in the analysis.
RESULTS: Seven studies on UC involving 431 patients were included in the analysis. The results showed that FMT had better efficacy than placebo (OR = 2.29, 95% CI 1.48-3.53, P = 0.0002). Subgroup analyses of influencing factors showed that frozen faeces from multiple donors delivered via the lower gastrointestinal tract had a better curative effect than placebo (OR = 2.76, 95% CI 1.59-4.79, P = 0.0003; OR = 2.93, 95% CI 1.67-5.71, P = 0.0002; and OR = 2.70, 95% CI 1.67-4.37, P < 0.0001); the difference in efficacy between mixed faeces from a single donor transplanted through the upper gastrointestinal tract and placebo was not significant(P = 0.05, P = 0.09 and P = 0.98). The analysis of side effects showed no significant difference between FMT and placebo (P = 0.43).
CONCLUSIONS: It may be safe and effective to transplant frozen faeces from multiple donors through the lower gastrointestinal tract to treat UC.

Entities:  

Keywords:  Meta-analysis; Microbiology; Ulcerative colitis

Mesh:

Year:  2020        PMID: 32388604     DOI: 10.1007/s00384-020-03599-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  7 in total

Review 1.  Fecal Microbiota Transplantation and Health Outcomes: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.

Authors:  Yapeng Li; Tingting Zhang; Jiahui Sun; Nanyang Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-27       Impact factor: 6.073

Review 2.  Essential updates 2020/2021: Colorectal diseases (benign)-Current topics in the surgical and medical treatment of benign colorectal diseases.

Authors:  Hiroshi Sawayama; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2022-01-25

3.  Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  Jessica Emily Green; Jessica A Davis; Michael Berk; Christopher Hair; Amy Loughman; David Castle; Eugene Athan; Andrew A Nierenberg; John F Cryan; Felice Jacka; Wolfgang Marx
Journal:  Gut Microbes       Date:  2020-11-09

Review 4.  Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Xiaolei Liu; Yan Li; Kaichun Wu; Yongquan Shi; Min Chen
Journal:  Gastroenterol Res Pract       Date:  2021-04-23       Impact factor: 2.260

5.  Kui Jie Tong Ameliorates Ulcerative Colitis by Regulating Gut Microbiota and NLRP3/Caspase-1 Classical Pyroptosis Signaling Pathway.

Authors:  Shigui Xue; Yan Xue; Danbo Dou; Huan Wu; Ping Zhang; Yang Gao; Yini Tang; Zehua Xia; Sen Yang; Sizhen Gu
Journal:  Dis Markers       Date:  2022-07-04       Impact factor: 3.464

Review 6.  Update on gut microbiota in gastrointestinal diseases.

Authors:  Atsushi Nishida; Kyohei Nishino; Masashi Ohno; Keitaro Sakai; Yuji Owaki; Yoshika Noda; Hirotsugu Imaeda
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

Review 7.  Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021.

Authors:  Tai Zhang; Beihua Zhang; Wende Tian; Fengyun Wang; Jiaqi Zhang; Xiangxue Ma; Yuchen Wei; Xudong Tang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.